Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neoplasms, Unknown Primary × ipatasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 7 Neoplasms 5 Solid Tumors 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Cancers 1 Skin Diseases 1 Neoplasms, Unknown Primary 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Carcinoma, Non-Small-Cell Lung 1 Breast Diseases 1

Interventions

Paclitaxel 2 Carboplatin 2 zenocutuzumab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 entrectinib 1 cobimetinib 1 belinostat 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Mebendazole 1 HhAntag691 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Cisplatin 1 CP protocol 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡